Table of Contents Author Guidelines Submit a Manuscript
International Journal of Nephrology
Volume 2011, Article ID 938651, 8 pages
http://dx.doi.org/10.4061/2011/938651
Review Article

Cardiorenal Syndrome Type 4—Cardiovascular Disease in Patients with Chronic Kidney Disease: Epidemiology, Pathogenesis, and Management

Department of Nephrology, Aristotle University of Thessaloniki, General Hospital of Thessaloniki “Hippokration”, Papanastasiou 50, 546 42 Thessaloniki, Greece

Received 30 August 2010; Accepted 3 January 2011

Academic Editor: Claudio Ronco

Copyright © 2011 Panagiotis Pateinakis and Aikaterini Papagianni. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Ronco, P. McCullough, S. D. Anker et al., “Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative,” European Heart Journal, vol. 31, no. 6, pp. 703–711, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. A. A. House, I. Anand, R. Bellomo et al., “Definition and classification of Cardio-Renal Syndromes: workgroup statements from the 7th ADQI Consensus Conference,” Nephrology Dialysis Transplantation, vol. 25, no. 5, pp. 1416–1420, 2010. View at Publisher · View at Google Scholar · View at PubMed
  3. National Kidney Foundation, “KDQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification,” American Journal of Kidney Diseases, vol. 39, no. 2, supplement 1, pp. S1–S266, 2002. View at Google Scholar
  4. M. Tonelli, N. Wiebe, B. Culleton et al., “Chronic kidney disease and mortality risk: a systematic review,” Journal of the American Society of Nephrology, vol. 17, no. 7, pp. 2034–2047, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. D. S. Keith, G. A. Nichols, C. M. Gullion, J. B. Brown, and D. H. Smith, “Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization,” Archives of Internal Medicine, vol. 164, no. 6, pp. 659–663, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. R. Vanholder, Z. Massy, A. Argiles et al., “Chronic kidney disease as cause of cardiovascular morbidity and mortality,” Nephrology Dialysis Transplantation, vol. 20, no. 6, pp. 1048–1056, 2005. View at Publisher · View at Google Scholar · View at PubMed
  7. US Renal Data System: USRDS 2009 Annual Data Report: Reference Tables, “Patient characteristics Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases,” 2009, http://www.usrds.org/2009/pdf/V2_06_09.PDF.
  8. N. J. McIntyre and M. W. Taal, “How to measure proteinuria?” Current Opinion in Nephrology and Hypertension, vol. 17, no. 6, pp. 600–603, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. C. D. A. Stehouwer and Y. M. Smulders, “Microalbuminuria and risk for cardiovascular disease: analysis of potential mechanisms,” Journal of the American Society of Nephrology, vol. 17, no. 8, pp. 2106–2111, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. H. L. Hillege, V. Fidler, G. F. H. Diercks et al., “Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population,” Circulation, vol. 106, no. 14, pp. 1777–1782, 2002. View at Publisher · View at Google Scholar
  11. T. Ninomiya, V. Perkovic, B. E. De Galan et al., “Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes,” Journal of the American Society of Nephrology, vol. 20, no. 8, pp. 1813–1821, 2009. View at Publisher · View at Google Scholar · View at PubMed
  12. B. C. Astor, S. I. Hallan, E. R. Miller, E. Yeung, and J. Coresh, “Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population,” American Journal of Epidemiology, vol. 167, no. 10, pp. 1226–1234, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. B. R. Hemmelgarn, B. J. Manns, A. Lloyd et al., “Relation between kidney function, proteinuria, and adverse outcomes,” Journal of the American Medical Association, vol. 303, no. 5, pp. 423–429, 2010. View at Publisher · View at Google Scholar · View at PubMed
  14. A. S. Go, G. M. Chertow, D. Fan, C. E. McCulloch, and C. Y. Hsu, “Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization,” New England Journal of Medicine, vol. 351, no. 13, pp. 1296–1305, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. K. Wattanakit, A. R. Folsom, E. Selvin, J. Coresh, A. T. Hirsch, and B. D. Weatherley, “Kidney function and risk of peripheral arterial disease: results from the Atherosclerosis Risk in Communities (ARIC) study,” Journal of the American Society of Nephrology, vol. 18, no. 2, pp. 629–636, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. A. Kottgen, S. D. Russell, L. R. Loehr et al., “Reduced kidney function as a risk factor for incident heart failure: the Atherosclerosis Risk in Communities (ARIC) study,” Journal of the American Society of Nephrology, vol. 18, no. 4, pp. 1307–1315, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. US Renal Data System: USRDS 2007 Annual Data Report: Reference Tables, “Patient characteristics Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2007,” August 2010, http://www.usrds.org/2009/ref/C_Ref_09.pdf.
  18. D. Weber-Mzell, P. Kotanko, M. Schumacher, W. Klein, and F. Skrabal, “Coronary anatomy predicts presence or absence of renal artery stenosis: a prospective study in patients undergoing cardiac catheterization for suspected coronary artery disease,” European Heart Journal, vol. 23, no. 21, pp. 1684–1691, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. C. M. Gibson, R. L. Dumaine, E. V. Gelfand et al., “Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13307 patients in five TIMI trials,” European Heart Journal, vol. 25, no. 22, pp. 1998–2005, 2004. View at Publisher · View at Google Scholar · View at PubMed
  20. N. S. Anavekar, J. J. V. McMurray, E. J. Velazquez et al., “Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction,” New England Journal of Medicine, vol. 351, no. 13, pp. 1285–1295, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. G. S. Hillis, B. L. Croal, K. G. Buchan et al., “Renal function and outcome from coronary artery bypass grafting: impact on mortality after a 2.3-year follow-up,” Circulation, vol. 113, no. 8, pp. 1056–1062, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. H. L. Hillege, A. R. J. Girbes, P. J. De Kam et al., “Renal function, neurohormonal activation, and survival in patients with chronic heart failure,” Circulation, vol. 102, no. 2, pp. 203–210, 2000. View at Google Scholar · View at Scopus
  23. C. E. Jackson, S. D. Solomon, H. C. Gerstein et al., “Albuminuria in chronic heart failure: prevalence and prognostic importance,” The Lancet, vol. 374, no. 9689, pp. 543–550, 2009. View at Publisher · View at Google Scholar
  24. P. A. McCullough, “Why is chronic kidney disease the "spoiler" for cardiovascular outcomes?” Journal of the American College of Cardiology, vol. 41, no. 5, pp. 725–728, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. L. C. Rump, K. Amann, S. Orth, and E. Ritz, “Sympathetic overactivity in renal disease: a window to understand progression and cardiovascular complications of uraemia?” Nephrology Dialysis Transplantation, vol. 15, no. 11, pp. 1735–1738, 2010. View at Google Scholar
  26. D. J. Kennedy, S. Vetteth, S. M. Periyasamy et al., “Central role for the cardiotonic steroid marinobufagenin in the pathogenesis of experimental uremic cardiomyopathy,” Hypertension, vol. 47, no. 3, pp. 488–495, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. J. Titze, “Water-free sodium accumulation,” Seminars in Dialysis, vol. 22, no. 3, pp. 253–255, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. S. Swaminathan and S. V. Shah, “Novel approaches targeted toward oxidative stress for the treatment of chronic kidney disease,” Current Opinion in Nephrology and Hypertension, vol. 17, no. 2, pp. 143–148, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. K. Amann, I. Rychlik, G. Miltenberger-Milteny, and E. Ritz, “Left ventricular hypertrophy in renal failure,” Kidney International, Supplement, vol. 54, no. 68, pp. S78–S85, 1998. View at Google Scholar · View at Scopus
  30. G. M. London, “Left ventricular alterations and end-stage renal disease,” Nephrology Dialysis Transplantation, vol. 17, no. 1, pp. 29–36, 2002. View at Google Scholar · View at Scopus
  31. K. Amann, C. Wanner, and E. Ritz, “Cross-talk between the kidney and the cardiovascular system,” Journal of the American Society of Nephrology, vol. 17, no. 8, pp. 2112–2119, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. P. S. Parfrey, R. N. Foley, J. D. Harnett, G. M. Kent, D. C. Murray, and P. E. Barre, “Outcome and risk factors for left ventricular disorders in chronic uraemia,” Nephrology Dialysis Transplantation, vol. 11, no. 7, pp. 1277–1285, 1996. View at Google Scholar · View at Scopus
  33. R. N. Foley, B. M. Curtis, E. W. Randell, and P. S. Parfrey, “Left ventricular hypertrophy in new hemodialysis patients without symptomatic cardiac disease,” Clinical Journal of the American Society of Nephrology, vol. 5, no. 5, pp. 805–813, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. K. Amann and E. Ritz, “The heart in renal failure: Morphological changes of the myocardium—new insights,” Journal of Clinical and Basic Cardiology, vol. 4, no. 2, pp. 109–113, 2001. View at Google Scholar · View at Scopus
  35. M. A. Losi, B. Memoli, C. Contaldi et al., “Myocardial fibrosis and diastolic dysfunction in patients on chronic haemodialysis,” Nephrology Dialysis Transplantation, vol. 25, no. 6, pp. 1950–1954, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. R. J. Middleton, P. S. Parfrey, and R. N. Foley, “Left ventricular hypertrophy in the renal patient,” Journal of the American Society of Nephrology, vol. 12, no. 5, pp. 1079–1084, 2001. View at Google Scholar · View at Scopus
  37. P. A. McCullough and K. R. Sandberg, “Chronic kidney disease and sudden death: strategies for prevention,” Blood Purification, vol. 22, no. 1, pp. 136–142, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. C. A. Herzog, J. M. Mangrum, and R. Passman, “Sudden cardiac death and dialysis patients,” Seminars in Dialysis, vol. 21, no. 4, pp. 300–307, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. L. S. Ibels, A. C. Alfrey, W. E. Huffer, P. W. Craswell, J. T. Anderson, and R. Weil III, “Arterial calcification and pathology in uremic patients undergoing dialysis,” American Journal of Medicine, vol. 66, no. 5, pp. 790–796, 1979. View at Google Scholar · View at Scopus
  40. J. Blacher, A. P. Guerin, B. Pannier, S. J. Marchais, M. E. Safar, and G. M. London, “Impact of aortic stiffness on survival in end-stage renal disease,” Circulation, vol. 99, no. 18, pp. 2434–2439, 1999. View at Google Scholar · View at Scopus
  41. Y. Ohya, K. Iseki, C. Iseki, T. Miyagi, K. Kinjo, and S. Takishita, “Increased pulse wave velocity is associated with low creatinine clearance and proteinuria in a screened cohort,” American Journal of Kidney Diseases, vol. 47, no. 5, pp. 790–797, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  42. U. Schwarz, M. Buzello, E. Ritz et al., “Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure,” Nephrology Dialysis Transplantation, vol. 15, no. 2, pp. 218–223, 2000. View at Google Scholar · View at Scopus
  43. M. Mizobuchi, D. Towler, and E. Slatopolsky, “Vascular calcification: the killer of patients with chronic kidney disease,” Journal of the American Society of Nephrology, vol. 20, no. 7, pp. 1453–1464, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. P. A. McCullough, M. Agarwal, and V. Agrawal, “Risks of coronary artery calcification in chronic kidney disease: do the same rules apply?” Nephrology, vol. 14, no. 4, pp. 428–436, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. J. Blacher, A. P. Guerin, B. Pannier, S. J. Marchais, and G. M. London, “Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease,” Hypertension, vol. 38, no. 4, pp. 938–942, 2001. View at Google Scholar · View at Scopus
  46. S. M. Moe and N. X. Chen, “Mechanisms of vascular calcification in chronic kidney disease,” Journal of the American Society of Nephrology, vol. 19, no. 2, pp. 213–216, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. G. M. London, S. J. Marchais, A. P. Guérin, P. Boutouyrie, F. Métivier, and M. C. De Vernejoul, “Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD,” Journal of the American Society of Nephrology, vol. 19, no. 9, pp. 1827–1835, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  48. V. M. Brandenburg and J. Floege, “Adynamic bone disease—bone and beyond,” NDT Plus, vol. 1, no. 3, pp. 135–147, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. T. E. Larsson, “The role of FGF-23 in CKD-MBD and cardiovascular disease: friend or foe?” Nephrology Dialysis Transplantation, vol. 25, no. 5, pp. 1376–1381, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  50. K. Amann, “Media calcification and intima calcification are distinct entities in chronic kidney disease,” Clinical Journal of the American Society of Nephrology, vol. 3, no. 6, pp. 1599–1605, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  51. T. Adragao, A. Pires, C. Lucas et al., “A simple vascular calcification score predicts cardiovascular risk in haemodialysis patients,” Nephrology Dialysis Transplantation, vol. 19, no. 6, pp. 1480–1488, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  52. S. Okuno, E. Ishimura, K. Kitatani et al., “Presence of abdominal aortic calcification is significantly associated with all-cause and cardiovascular mortality in maintenance hemodialysis patients,” American Journal of Kidney Diseases, vol. 49, no. 3, pp. 417–425, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  53. J. Braun, M. Oldendorf, W. Moshage, R. Heidler, E. Zeitler, and F. C. Luft, “Electron beam computed tomography in the evaluation of cardiac calcifications in chronic dialysis patients,” American Journal of Kidney Diseases, vol. 27, no. 3, pp. 394–401, 1996. View at Google Scholar · View at Scopus
  54. W. G. Goodman, J. Goldin, B. D. Kuizon et al., “Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis,” New England Journal of Medicine, vol. 342, no. 20, pp. 1478–1483, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  55. P. A. McCullough, K. M. Chinnaiyan, V. Agrawal, E. Danielewicz, and G. S. Abela, “Amplification of atherosclerotic calcification and Mönckeberg's sclerosis: a spectrum of the same disease process,” Advances in Chronic Kidney Disease, vol. 15, no. 4, pp. 396–412, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  56. P. A. McCullough, V. Agrawal, E. Danielewicz, and G. S. Abela, “Accelerated atherosclerotic calcification and mönckeberg's sclerosis: a continuum of advanced vascular pathology in chronic kidney disease,” Clinical Journal of the American Society of Nephrology, vol. 3, no. 6, pp. 1585–1598, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  57. P. A. McCullough and K. M. Chinnaiyan, “Annual progression of coronary calcification in trials of preventive therapies a systematic review,” Archives of Internal Medicine, vol. 169, no. 22, pp. 2064–2070, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  58. S. Nakamura, H. Ishibashi-Ueda, S. Niizuma, F. Yoshihara, T. Horio, and Y. Kawano, “Coronary calcification in patients with chronic kidney disease and coronary artery disease,” Clinical Journal of the American Society of Nephrology, vol. 4, no. 12, pp. 1892–1900, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  59. A. N. Wade and M. P. Reilly, “Coronary calcification in chronic kidney disease: morphology, mechanisms and mortality,” Clinical Journal of the American Society of Nephrology, vol. 4, no. 12, pp. 1883–1885, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  60. R. Watanabe, M. M. Lemos, S. R. Manfredi, S. A. Draibe, and M. E. F. Canziani, “Impact of cardiovascular calcification in nondialyzed patients after 24 months of follow-up,” Clinical Journal of the American Society of Nephrology, vol. 5, no. 2, pp. 189–194, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  61. G. A. Block, P. Raggi, A. Bellasi, L. Kooienga, and D. M. Spiegel, “Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients,” Kidney International, vol. 71, no. 5, pp. 438–441, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  62. D. M. Charytan, R. E. Kuntz, M. Garshick, S. Candia, M. F. Khan, and L. Mauri, “Location of acute coronary artery thromboses in patients with and without chronic kidney disease,” Kidney International, vol. 75, no. 1, pp. 80–87, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  63. C. DeFilippi, S. Wasserman, S. Rosanio et al., “Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis,” Journal of the American Medical Association, vol. 290, no. 3, pp. 353–359, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  64. T. Hayashi, Y. Obi, T. Kimura et al., “Cardiac troponin T predicts occult coronary artery stenosis in patients with chronic kidney disease at the start of renal replacement therapy,” Nephrology Dialysis Transplantation, vol. 23, no. 9, pp. 2936–2942, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  65. D. Bolignano, G. Coppolino, A. Lacquaniti, and M. Buemi, “From kidney to cardiovascular diseases: NGAL as a biomarker beyond the confines of nephrology,” European Journal of Clinical Investigation, vol. 40, no. 3, pp. 273–276, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  66. Kidney Disease Improving Global Outcomes (KDIGO), “Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease—mineral and bone disorder (CKD—MBD). Vascular calcification,” Kidney International, vol. 76, supplement 113, pp. S22–S49, 2009. View at Google Scholar
  67. D. Rucker and M. Tonelli, “Cardiovascular risk and management in chronic kidney disease,” Nature Reviews Nephrology, vol. 5, no. 5, pp. 287–296, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  68. C. Wanner, V. Krane, W. März et al., “Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis,” New England Journal of Medicine, vol. 353, no. 3, pp. 238–248, 2005. View at Publisher · View at Google Scholar · View at PubMed
  69. B. C. Fellström, A. G. Jardine, R. E. Schmieder et al., “Rosuvastatin and cardiovascular events in patients undergoing hemodialysis,” New England Journal of Medicine, vol. 360, no. 14, pp. 1395–1407, 2009. View at Publisher · View at Google Scholar · View at PubMed
  70. G. R. Bailie, G. Eisele, L. Liu et al., “Patterns of medication use in the RRI-CKD study: focus on medications with cardiovasculars effects,” Nephrology Dialysis Transplantation, vol. 20, no. 6, pp. 1110–1115, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  71. K. Kalantar-Zadeh, G. Block, M. H. Humphreys, and J. D. Kopple, “Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients,” Kidney International, vol. 63, no. 3, pp. 793–808, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  72. R. Pecoits-Filho, B. Lindholm, and P. Stenvinkel, “The malnutrition, inflammation, and atherosclerosis (MIA) syndrome—the heart of the matter,” Nephrology Dialysis Transplantation, vol. 17, supplement 11, pp. 28–31, 2002. View at Google Scholar
  73. Y. Liu, J. Coresh, J. A. Eustace et al., “Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition,” Journal of the American Medical Association, vol. 291, no. 4, pp. 451–459, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  74. E. F. Unger, A. M. Thompson, M. J. Blank, and R. Temple, “Erythropoiesis-stimulating agents—time for a reevaluation,” New England Journal of Medicine, vol. 362, no. 3, pp. 189–192, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  75. L. J. Appel, J. T. Wright Jr., T. Greene et al., “Intensive blood-pressure control in hypertensive chronic kidney disease,” New England Journal of Medicine, vol. 363, no. 10, pp. 918–929, 2010. View at Publisher · View at Google Scholar · View at PubMed
  76. G. Schernthaner, E. Ritz, and G. H. Schernthaner, “Strict glycaemic control in diabetic patients with CKD or ESRD: beneficial or deadly?” Nephrology Dialysis Transplantation, vol. 25, no. 7, pp. 2044–2047, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  77. J. F. Mann, R. E. Schmieder, M. McQueen et al., “Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial,” The Lancet, vol. 372, no. 9638, pp. 547–553, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  78. R. Agarwal, “Individualizing decision-making—resurrecting the doctor-patient relationship in the anemia debate,” Clinical Journal of the American Society of Nephrology, vol. 5, no. 7, pp. 1340–1346, 2010. View at Publisher · View at Google Scholar · View at PubMed
  79. A. K. Singh, “ESAs in dialysis patients: are you a hedgehog or a fox?” Journal of the American Society of Nephrology, vol. 21, no. 4, pp. 543–546, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  80. E.V.O.L.V.E. Trial™, “EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events,” November 2010, http://clinicaltrials.gov/ct2/show/NCT00345839.
  81. “Study of Heart and Renal Protection (SHARP),” November 2010, http://www.ctsu.ox.ac.uk/~sharp/.
  82. Kidney Disease Outcomes Quality Initiative (K/DOQI), “Clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease,” American Journal of Kidney Diseases, vol. 43, no. 5, supplement 1, pp. S1–S290, 2004. View at Google Scholar
  83. Kidney Disease Outcomes Quality Initiative (K/DOQI), “Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease,” American Journal of Kidney Diseases, vol. 49, no. 2, supplement 2, pp. S12–S154, 2007. View at Google Scholar
  84. A. Levin, B. Hemmelgarn, B. Culleton et al., “Guidelines for the management of chronic kidney disease,” Canadian Medical Association Journal, vol. 179, no. 11, pp. 1154–1162, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  85. T. P. Peacock, Z. K. Shihabi, A. J. Bleyer et al., “Comparison of glycated albumin and hemoglobin A(1c) levels in diabetic subjects on hemodialysis,” Kidney International, vol. 73, no. 9, pp. 1062–1068, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  86. B. C. H. Kwan, F. Kronenberg, S. Beddhu, and A. K. Cheung, “Lipoprotein metabolism and lipid management in chronic kidney disease,” Journal of the American Society of Nephrology, vol. 18, no. 4, pp. 1246–1261, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  87. Kidney Disease Improving Global Outcomes (KDIGO), Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease—Mineral and Bone Disorder (CKD—MBD), “Treatment of CKD-MBD targeted at lowering high serum phosphorus and maintaining serum calcium,” Kidney International, vol. 76, supplement 113, pp. S50–S69, 2009. View at Google Scholar
  88. Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease—Mineral and Bone Disorder (CKD—MBD), “Treatment of abnormal PTH levels in CKD-MBD,” Kidney International, vol. 76, supplement 113, pp. S70–S89, 2009. View at Google Scholar
  89. R. Mehrota and R. Agarwal, “End stage renal disease and dialysis,” NephSAP, vol. 7, no. 6, pp. 35–425, 2008. View at Google Scholar
  90. J. O. Burton, H. J. Jefferies, N. M. Selby, and C. W. McIntyre, “Hemodialysis-induced cardiac injury: determinants and associated outcomes,” Clinical Journal of the American Society of Nephrology, vol. 4, no. 5, pp. 914–920, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus